ALV003

BIOLOGICAL4 trials

Sponsors

Alvine Pharmaceuticals Inc.

Conditions

Celiac Disease

Phase 1

Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal

CompletedNCT00669825

Alvine Pharmaceuticals Inc.Celiac Disease

Start: 2008-03-31End: 2008-10-31Target: 36Updated: 2010-02-19

Phase 2

Safety and Efficacy of ALV003 for the Treatment of Celiac Disease

CompletedNCT00959114

Alvine Pharmaceuticals Inc.Celiac Disease

Start: 2009-08-31End: 2010-10-31Updated: 2012-08-06

Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease

CompletedNCT01255696

Alvine Pharmaceuticals Inc.Celiac Disease

Start: 2010-11-30End: 2011-06-30Updated: 2012-08-06

Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients

Alvine Pharmaceuticals Inc.Celiac Disease

Start: 2013-08-31End: 2015-06-30Target: 500Updated: 2014-12-17

Related Papers

Modeling Symptom Severity and Estimated Gluten Ingestion in Celiac Disease Patients on a Gluten-Free Diet

International Journal of Celiac Disease2020-08-03

Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet.

2019-10-0831 citations

Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet.

2017-07-2854 citations

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.

2016-11-1593 citations

Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.

2014-02-25165 citations